Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

To show safety and efficacy of half fluence cross-linking with phakic IOL implantation in cases of post-LASIK regression

Poster Details

First Author: P.Subudhi INDIA

Co Author(s):    S. Patro   B. Subudhi   S. Sitaram              

Abstract Details

Purpose:

To show efficacy of half fluence cross linking with intraocular implantable phakic collamer lens (IPCL, Care group inc.) implantation in cases of post lasik regression.

Setting:

Ruby Eye Hospital, Berhampur, Odisha, India

Methods:

10 eyes of 5 patients were analysed for post lasik refractive error. All patients were investigated with pentacam to look for signs of ectasia. All had progressive increase in refractive error but none had topographic signs of classic ectasia. Eligible patients underwent half fluence cross linking. After 3 months they were scheduled for intraocular phakic IOL implantation. Eyes were targeted for emmetropia. Mean pre operative uncorrected visual acuity was 1.4 decimals in logmars. Mean pre operative refractive error corrected 12.65D (Min: 6 and Max : 22). Mean preoperative simulated keratometry 36.3 D ( Min: 34D and max: 38.5).

Results:

Mean post operative spherical equivalent recorded was 0.75D (Min: 0.25 and Max: 1.37). Mean Post op unaided visual acuity recorded 0.13 logmar units +/-0.12 ( Min 0 and Max 0.3). Patients had mean follow up of 1.54 years +/-0.33 and vision was stable during this period. Post operative keratometry remained stable during the follow up period. Contrast sensitivity at 6 months improved significantly with p value <0.0001. Corneal thickness showed no signs of alteration.

Conclusions:

Half fluence collagen cross linking in combination with sequential implantation of phakic iol in cases of post lasik regression can be considered as an effective and stable procedure providing successful outcome.

Financial Disclosure:

None

Back to Poster listing